Terumo Corp
TSE:4543

Watchlist Manager
Terumo Corp Logo
Terumo Corp
TSE:4543
Watchlist
Price: 3 035 JPY -0.78% Market Closed
Market Cap: 4.5T JPY
Have any thoughts about
Terumo Corp?
Write Note

Net Margin
Terumo Corp

12.1%
Current
12%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
119.5B
/
Revenue
986.7B

Net Margin Across Competitors

Country JP
Market Cap 4.5T JPY
Net Margin
12%
Country US
Market Cap 199B USD
Net Margin
14%
Country US
Market Cap 191.3B USD
Net Margin
29%
Country US
Market Cap 141.3B USD
Net Margin
16%
Country US
Market Cap 134.2B USD
Net Margin
11%
Country IE
Market Cap 104.6B USD
Net Margin
13%
Country US
Market Cap 65.6B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.5B USD
Net Margin
74%
Country CN
Market Cap 311.1B CNY
Net Margin
33%
Country US
Market Cap 36.1B USD
Net Margin
9%
No Stocks Found

Terumo Corp
Glance View

Market Cap
4.5T JPY
Industry
Health Care

In the bustling corridors of Tokyo, Terumo Corporation stands as a testament to Japan's prowess in medical innovation, deeply rooted in a legacy that began over 90 years ago. Born from the vision of a group of scientists aiming to improve Japan’s healthcare system, Terumo embarked on its journey by developing high-quality thermometers. This modest start set the stage for what would become a global leader in medical technology. Anchored by its commitment to enhancing patient care and healthcare practices, Terumo carved out a significant niche by focusing on cardiovascular systems, blood transfusion, and cell therapy technologies. As the company grew, it systematically increased its range, moving into areas such as vascular intervention and diabetes care, aligning with evolving medical needs around the globe. Today, Terumo generates its revenue through a multi-faceted business model that thrives on innovation and globalization. It operates through several segments: Cardiovascular, General Hospital, and Blood Management. The Cardiovascular division, a major revenue driver, offers products ranging from stents to heart-lung machines used in cardiac surgeries. Meanwhile, the General Hospital unit provides hospital equipment like infusion pumps and syringe systems, while the Blood Management segment is renowned for its blood and cell processing systems. Terumo’s ability to innovate within these domains enhances its competitive edge by delivering cutting-edge medical solutions. By balancing its expansive product portfolio with a strong focus on research and development, the company not only sustains but frequently advances the standards of modern healthcare, ensuring its continued success in diverse international markets.

Intrinsic Value
2 434.6 JPY
Overvaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
119.5B
/
Revenue
986.7B
What is the Net Margin of Terumo Corp?

Based on Terumo Corp's most recent financial statements, the company has Net Margin of 12.1%.